Player Avatar zzlangerhans (99.81) Submitted: 8/8/2011 8:00:03 PM : Outperform Start Price: $13.12 INCY Score: +13.82

At one point today Incyte stock wasn't far from their one year low. I'm sure that's not what management had in mind for the week that the FDA accepted the NDA for ruxolitinib with a six month priority review. That's a far cry from prices over 20 that were seen earlier in the summer, and it makes Incyte a prime candidate for a rebound given the deep pipeline and hardwired catalyst in early December.

Featured Broker Partners